DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Alkermes
plc (Nasdaq: ALKS) today announced plans to present a poster
related to nemvaleukin alfa (nemvaleukin), the company's novel,
investigational, engineered interleukin-2 (IL-2) variant
immunotherapy, at the American Society of Clinical Oncology (ASCO)
Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical
data related to advanced GI cancers from ARTISTRY-1, a phase 1/2
study evaluating the tolerability and efficacy of nemvaleukin
administered intravenously as a monotherapy and in combination with
pembrolizumab (KEYTRUDA®), and preclinical data
from the study of nemvaleukin in combination with novel
agents in GI cancers.
Details of the presentation are as follows:
Abstract: 659
Title: Nemvaleukin alfa combination therapy for
gastrointestinal (GI) cancers: preclinical evidence and clinical
data from the ARTISTRY-1 trial
Presenter: Ulka N. Vaishampayan, M.D., Professor,
Internal Medicine, Division of Hematology/Oncology, University of Michigan
Presentation Date: The poster, along with a pre-recorded
presentation, will be available on the ASCO GI virtual meeting
platform beginning Jan. 20, 2022.
About Nemvaleukin Alfa ("nemvaleukin")
Nemvaleukin is
an investigational, novel, engineered fusion protein comprised of
modified interleukin-2 (IL-2) and the high affinity IL-2 alpha
receptor chain, designed to preferentially expand tumor-killing
immune cells while avoiding the activation of immunosuppressive
cells by selectively binding to the intermediate-affinity IL-2
receptor complex. The selectivity of nemvaleukin is designed to
leverage the proven anti-tumor effects of existing IL-2 therapy
while mitigating certain limitations.
About the Nemvaleukin Clinical Development
Program
ARTISTRY is an Alkermes-sponsored clinical development program
evaluating nemvaleukin as a potential immunotherapy for cancer. The
ARTISTRY program is comprised of multiple clinical trials
evaluating intravenous and subcutaneous dosing of nemvaleukin, both
as a monotherapy and in combination with the anti-PD-1 therapy
KEYTRUDA® (pembrolizumab) in patients with advanced
solid tumors. Ongoing trials in the ARTISTRY program
include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3, ARTISTRY-6 and
ARTISTRY-7.
About Alkermes plc
Alkermes plc is a
fully-integrated, global biopharmaceutical company developing
innovative medicines in the fields of neuroscience and oncology.
The company has a portfolio of proprietary commercial products
focused on addiction, schizophrenia and bipolar I disorder, and a
pipeline of product candidates in development for neurodegenerative
disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D
center in Waltham, Massachusetts;
a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in
Wilmington, Ohio. For more
information, please visit Alkermes' website at
www.alkermes.com.
KEYTRUDA® is a registered trademark of Merck Sharp
& Dohme Corp., a subsidiary of Merck & Co., Inc.,
Kenilworth, NJ, USA.
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781
609 6377
For Media: Sourojit Bhowmick, Ph.D., +1 781 609 6397
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg